IR20: Addax Biosciences was awarded as best health economy StartUp in Piedmont
Addax Biosciences won the IR20 Innovation and Research Award, conferred by Piedmont Region to heighten the best projects carried out by companies, start-ups, public and private research institutions and laboratories.
A qualified jury of experts, composed of outstanding exponents of the academic and scientific sphere, examined 97 applications. The Addax Biosciences project, “Towards a Formalin Free hospital”, was awarded as best StartuP the “Health Economy” category during a ceremony organized at the Egyptian Museum in Turin, one of the most important museums in Italy.
The project presented by Addax Biosciences aims at the progressive replacement of Formalin (a chemical reagent based on formaldehyde, still widely used in histopathology laboratories despite its recognized toxicity and carcinogenicity) with an innovative histological fixative: GAF. Created by Addax Biosciences as a result of years of scientific research, this revolutionary product has been patented internationally and subjected to multiple validation processes. Its use protects the health of the workers involved in the handling of pathological samples and reduces the safety-related costs of using a toxic product (in terms of precautions, devices and legal responsibility) without compromising diagnostic precision.
The recognition by the Piedmont Region as part of the IR20 initiative aims to ensure a wide spreading of the project, also through a dedicated promotional campaign. This will consent to enhance GAF’s potential and accelerate the process of replacing Formalin with this product, therefore generating a significantly beneficial social and economic impact.